Changes in hemostatic variables induced by estrogen replacement therapy: Comparison of transdermal and oral administration in a crossover-designed study

Gynecologic and Obstetric Investigation

Volumn 65, Issue 1, 2008, Pages 47-51

  Fait, Tomas ^a   Vrablik, Michal ^a   Zizka, Zdenek ^a   Kostirova, Milada ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

D dimers; Estrogen replacement therapy; Plasminogen activator inhibitor 1; Thromboembolism; Tissue factor pathway inhibitor

Indexed keywords

ANTITHROMBIN III; D DIMER; ESTRADIOL; ESTROFEM; ESTROGEN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ADMINISTRATION ROUTE; EARLY MENOPAUSE; ESTROGEN THERAPY; FEMALE; HEMOSTASIS; HUMAN; HYSTERECTOMY; OVARIECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ANTITHROMBIN III; CROSS-OVER STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FIBRINOGEN; HEMOSTASIS; HUMANS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; RISK FACTORS; THROMBOEMBOLISM;

EID: 38349175957     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107492     Document Type: Article

References (26)

1. Notelovitz M: The clinical practice impact of the Women's Health Initiative: political vs biologic correctness. Maturitas 2003;44:3-9.
2. Broze GJ Jr: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995;6(Suppl 1):S7-S13.
3. Lwaleed BA, Bass PS: Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006;208:327-329.
4. Bognacki J, Hammelburger J: Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1995;6(Suppl 1):S65-S72.
5. Dahm A, Van Hylckama Vlieg A, Bendz B, et al: Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003;101:4387-4392.
6. Maruna P: Proteins of Acute Stage (in Czech). Prague, Maxdorf, 2004, p 282.
7. Thögersen AM, Jansson JH, Boman K, et al: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-2247.
8. Modena MG, Sismondi P, Mueck AO, et al: New evidence regarding hormone replacement therapies is urgently required. Transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 2005;52:1-10.
9. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group (ESTHER): Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432.
10. Salpeter SR, Walsh JM, Greyber E, et al: Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804.
11. Sowers MR, Matthews KA, Jannausch M, et al: Hemostatic factors and estrogen during the menopausal transition. J Clin Endocrinol Metab 2005;90:5942-5948.
12. Peverill RE, Teede HJ, Smolich JJ, et al: Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII. Clin Sci (Lond) 2001;101:93-99.
13. Bladbjerg EM, Skouby SO, Andersen LF, et al: Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 2002;17:3235-3241.
14. Bladbjerg EM, Madsen JS, Kristensen SR, et al: Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003;1:1208-1214.
15. Hoibraaten E, Qvigstad E, Andersen TO, et al: The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trial. Thromb Haemost 2001;85:775-781.
16. Hoke M, Kyrle PA, Minar E, et al: Tissue factor pathway inhibitor and the risk of recurrent venous tromboembolism. Thromb Haemost 2005;94:787-790.
17. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, et al: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625.
18. Koh KK, Mincemoyer R, Bui MN, et al: Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-690.
19. Martínez C, Basurto L, Zárate A, et al: Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas 2005;50:39-43.
20. Post MS, van der Mooren MJ, van Baal WM, et al: Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol 2003;189:1221-1227.
21. Lowe GD, Upton MN, Rumley A, et al: Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001;86:550-556.
22. Koh KK, Shin MS, Sakuma I, et al: Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 2004;24:1516-1521.
23. Madsen JS, Kristensen SR, Gram J, et al: Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women. J Thromb Haemost 2003;1:1984-1991.
24. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al: Effects of oral and transdermal estrogen/ progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-3078.
25. Gottsäter A, Rendell M, Hulthén UL, et al: Hormone replacement therapy in healthy postmenopausal women: a randomised, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med 2001;249:237-246.
26. Writing Group for the 3rd European Conference on Sex Steroids and Cardiovascular Diseases: The European Consensus Development Conference 2002: Sex Steroids and Cardiovascular Diseases. On the route to combined evidence from OC and HRT/ERT. Maturitas 2003;44:69-82.